Phosphorylation of the Fas-associated death domain (FADD) protein sensitizes cancer cells to various chemotherapeutics. However, the molecular mechanism underlying chemosensitization by phosphorylated FADD (P-FADD) is poorly understood. In this study, we describe the physical interactions and functional interplay between Polo-like kinase 1 (Plk1) and FADD. Plk1 phosphorylates FADD at Ser-194 in response to treatment with taxol. Overexpression of a phosphorylation-mimicking mutant, FADD S194D, caused degradation of Plk1 in an ubiquitin-independent manner, and delayed cytokinesis, consistent with the expected cellular phenotype of Plk1 deficiency. This demonstrates that Plk1 is regulated via a negative feedback loop by its substrate, FADD. Overexpression of FADD S194D sensitized HeLa cells to a low dose of taxol independently of caspase activation, whereas overexpression of FADD S194D resulted in caspase activation in response to a high dose of taxol. Therefore, we examined whether the death potential of P-FADD affected Plk1-mediated tumorigenesis. Transfection of FADD S194D inhibited colony formation by Plk1-overexpressing HeLa cells (HeLa-Plk1). Moreover, overexpression of FADD S194D suppressed tumorigenesis in nude mice xenografted with HeLa-Plk1. Therefore, this study reports the first in vivo validation of tumor-suppressing activity of P-FADD. Collectively, our data demonstrate that in response to taxol, Plk1 endows death-promoting and tumor-suppressor functions to its substrate, FADD.
Introduction
Polo-like kinase 1 (Plk1) is a well-characterized oncoprotein that is highly expressed in various cancer tissues (Eckerdt et al., 2005) . Overexpression of Plk1 in murine fibroblasts (that is, NIH3T3 cells) yielded a transformed phenotype in culture, with large cells having multiple fragmented nuclei, and caused tumor formation in nude mice (Smith et al., 1997) . However, Plk1 heterozygous mice also developed spontaneous tumors (Lu et al., 2008) , implying that regulation of Plk1 expression is important in preventing tumorigenesis. Many studies have shown correlations between Plk1 expression and poor prognosis in various cancers (Takai et al., 2005) . Therefore, elevated expression of Plk1 is considered as a novel prognostic marker in many types of cancer. Several Plk1 inhibitors are currently under investigation, including ON01910, BI2536, GSK461364A, DH166 and BI6727 (Gumireddy et al., 2005; Steegmaier et al., 2007; Gilmartin et al., 2009; Rudolph et al., 2009; Zhang et al., 2009) .
Plk1 is a 67 kDa serine/threonine protein kinase that has pivotal roles in several G 2 -and M-phase-related events, namely centrosome maturation, a-tubulin association with centrosomes, bipolar spindle formation, chromosome segregation and cytokinesis (Barr et al., 2004; Strebhardt and Ullrich, 2006) . Plk1 has conserved sequence motifs in two domains: the N-terminal serine/ threonine catalytic domain and the C-terminal noncatalytic domain, the latter of which is termed the polobox domain (PBD). The PBD has an important role in regulating interactions with substrates (Cheng et al., 2003) . Consistent with the prominent role of Plk1 in G 2 / M phase, Plk1 expression and activity remain low throughout G 0 , G 1 and S phases, rise in G 2 phase and peak during M phase (Strebhardt and Ullrich, 2006) . Elevated expression of Plk1 during G 2 /M phase promotes the degradation of Plk1 by anaphase-promoting complex/cyclosome via the ubiquitin-proteasome pathway, as cells exit mitosis (Lindon and Pines, 2004) .
Fas-associated death domain-containing protein (FADD) was first identified as an adapter molecule involved in formation of a death-inducing signaling complex upon Fas stimulation (Peter et al., 1999) . The FADD protein mediates two types of cell death pathways (Vanden Berghe et al., 2004) . The FADD protein is recruited to the death receptor via a death domain (DD) and interacts with the death effector domain of caspase-8 through a FADD-intrinsic death effector domain. The FADD/caspase-8 interaction provides a platform for caspase-8 activation and subsequently leads to activation of caspase-3, a hallmark of apoptosis.
In addition, FADD has an important role in necrosis. Necrotic cell death was stimulated by oligomerization of FADD-death domain in caspase-8-inactivated Jurkat cells (Kawahara et al., 1998) . Furthermore, FADD binds to RIP1 (receptor-interacting protein 1) kinase, an important necrotic marker (Vanden Berghe et al., 2004) . Consistent with these characteristics, overexpression of FADD-death domain sensitized TNF-resistant U937 and NIH3T3 cells, leading to necrotic cell death (Khwaja and Tatton, 1999) .
The phosphorylation status of FADD serves as a valuable marker for human cancer progression (Shimada et al., 2005) . Expression of phosphorylated FADD (P-FADD) is lower in cancer cells than in normal epithelial cells. Expression of P-FADD increases in response to chemotherapeutic treatments, and overexpression of P-FADD sensitizes cancer cells to such materials. However, expression of a phosphorylationdeficient FADD mutant (FADD S194A) abolished sensitization to chemotherapeutics (Shimada et al., 2002 (Shimada et al., , 2004 (Shimada et al., , 2005 , prompting investigators to identify the kinase(s) responsible for the phosphorylation of FADD. Casein kinase 1a (CK1a) was shown to phosphorylate serine 194 of FADD (Alappat et al., 2005) , and an unknown kinase of B70 kDa was thought to phosphorylate FADD (Scaffidi et al., 2000) .
This study demonstrates that Plk1 phosphorylates FADD upon taxol treatment and thereby promotes degradation of Plk1, resulting in negative feedback regulation. Moreover, phosphorylation of FADD confers death-promoting potential and tumor-suppressing activity. In this study, we describe a cell cycle kinase that performs an antiproliferative role in response to the anticancer drug, taxol.
Results

FADD interacts with Plk1 upon taxol treatment
Expression of FADD is often reduced in cancerous tissues, including gastric cancer (Yang et al., 2005; Matsuyoshi et al., 2006; Yoo et al., 2007; Xu et al., 2009) . To elucidate the molecular mechanisms underlying this phenomenon, we searched for FADD interactors among complementary DNAs that displayed differential expression patterns in healthy and cancerous gastric tissues from Korean patients. Briefly, genes displaying elevated or reduced expression in gastric cancer tissues were translated in vitro, and glutathione S-transferase (GST) pull-down assays were performed on GST-tagged FADD and the in vitro-translated genes. Several proteins interacted with FADD, including Plk1.
The FADD-Plk1 interactions were further examined in HeLa cells (Figures 1a and b) . Immunoprecipitation and subsequent immunoblotting with the anti-FADD antibody revealed that FADD and Plk1 did not interact in unstimulated HeLa cells. However, FADD and Plk1 formed complexes in taxol-treated HeLa cells in a timeand dose-dependent manner. Moreover, FADD and Plk1 did not colocalize in untreated cells; however, they colocalized in taxol-treated cells (Supplementary Figure 1, upper panel) . In addition, taxol treatment significantly increased the expressions of P-FADD and Plk1, demonstrating their colocalization upon taxol treatment (Supplementary Figure 1, bottom panel) .
To further investigate the formation of these complexes by Plk1 and FADD, we performed gel-filtration analysis using Superose 6 column (GE Healthcare, Piscataway, NJ, USA). The majority of endogenous FADD appeared in low-molecular-weight (B43 kDa) fractions, and Plk1 was found in fractions that ranged in molecular weight from B43 to 42000 kDa. However, a significant amount of Plk1 and FADD formed highmolecular-weight (42000 kDa) complexes in taxol-treated HeLa cells (Figure 1c) . This raised the possibility that FADD and Plk1 form complexes with a molecular weight of 42000 kDa in taxol-treated HeLa cells.
To identify the Plk1 domain responsible for binding to FADD, the GST pull-down assay was performed using GST-tagged truncated mutants of Plk1. These mutants encompassed the kinase domain (that is, Plk1-K, amino acid residues 1-308) or the PBD (that is, Plk1-PBD, amino acid residues 306-604), together with in vitro-translated FADD. The FADD protein bound specifically to the Plk1-PBD, the known binding domain to its substrate proteins, but not to the Plk1-K domain (Figure 1d ).
Plk1 phosphorylates FADD at Ser-194
Next, we determined if FADD-Plk1 interactions led to the phosphorylation of FADD. Western blot analysis with an anti-P-FADD antibody revealed a band that formed in a time-and dose-dependent manner in taxoltreated HeLa cells, indicating the presence of P-FADD (Figures 1a and b) . Next, we examined whether Plk1 was responsible for phosphorylation of FADD in taxoltreated HeLa cells. Cells were transfected with Plk1-specific small interfering RNA to promote the transient depletion of Plk1. Phosphorylation of FADD was clearly inhibited in Plk1-depleted, taxol-treated HeLa cells (Figure 2a ). The Plk1 kinase assay was next performed in vitro using GST-FADD as a substrate. At 36 h after transfection with FLAG-tagged Plk1 wild type or kinase dead, cells were treated with 25 nM taxol for 12 h. After taxol stimulation, Plk1 was immunoprecipitated using an anti-FLAG antibody. The immunoprecipitates were used to perform an in vitro kinase assay. Plk1 wild type, but not Plk1 kinase dead, phosphorylated GST-FADD in vitro, demonstrating the specificity of phosphorylation (Figure 2b ). Moreover, P-FADD was increased by forced expression of Plk1 T210D, a constitutively activated mutant form of Plk1, when compared with cells transfected with Plk1 T210A, a kinase-defective mutant form of Plk1 (Supplementary Figure 2) .
We reasoned that if Plk1 was the binding partner of FADD, then GST-FADD-mediated depletion of endogenous FADD from taxol-treated HeLa cells should result in the concordant loss of Plk1 expression and kinase activity. To test this idea, we depleted cell lysates via sequential pull-downs with GST-FADD (Figure 2c ).
After seven pull-downs, the amount of immunoprecipitated Plk1 in the lysates was significantly lower than in the GST-mediated pull-down lysates. These data demonstrate that Plk1 interacts with FADD and phosphorylates FADD in taxol-treated HeLa cells. In order to further confirm the phosphorylation of FADD by Plk1, the in vitro kinase assay was performed. Plk1 efficiently phosphorylated FADD, whereas Plk2 and Plk3 did not (Supplementary Figure 3) . Next, to assess whether Plk1 phosphorylates FADD at Ser-194, a previously identified site (Scaffidi et al., 2000) , we generated a GST-fusion protein containing the FADD substitution mutant (S194A). Plk1 did not phosphorylate the FADD S194A mutant (Figure 2d ). However, it should be noted that Ser-194 is not embedded in the consensus motif of Plk1 substrates (that is, E/D-X-S/T) (Nakajima et al., 2003) . Therefore, we further examined whether the expression level of P-FADD changed by the transfection of FADD S194A. P-FADD expression was decreased in FADD S194A-transfected cells when compared with MOCK-transfected cells (Supplementary Figure 4) . Collectively, our data indicate that Ser-194 residue of FADD is phosphorylated by Plk1. However, Plk1 has been shown to phosphorylate other proteins that do not contain this consensus motif, such as GRASP65 and vimentin (Preisinger et al., 2005; Yamaguchi et al., 2005) . P-FADD mediates the degradation of Plk1 in an Ub-independent and proteasome-dependent manner We transfected FADD into HeLa cells in order to understand the implication of the interaction between FADD and Plk1. HeLa cells transfected with FADD S194A and FADD S194D displayed differential Plk1 expression levels. Plk1 expression decreased in a dosedependent manner in cells transfected with FADD S194D, but not in cells containing FADD S194A Whole cell lysates (WCLs) were immunoblotted with the specified antibodies. The equivalency of loading was confirmed by glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (c) Equal amounts of HeLa lysates were fractionated by fast protein liquid chromatography (FPLC) on Superose 6 column after stimulation with 25 nM taxol or dimethylsulfoxide (DMSO) for 12 h. Fractions were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and then subjected to immunoblotting assays using the indicated antibodies. The elution profile of the molecular weight (MW) standards is shown at the top. (d) GST pull-down assays were performed by incubating 35 S-labeled FADD with GST, GST-full-length Plk1 or truncated mutants Plk1 (Plk1-K, amino acid residues 1-308; Plk1-PBD, amino acid residues 306-604) and the results were visualized by autoradiography or Ponceau S staining. The right panel depicts a schematic drawing of Plk1 deletion mutants. WB, western blot; K, kinase domain, PB, polo-box.
( Figure 3a) . Moreover, Plk1 synthesized de novo was degraded faster in FADD S194D-expressing cells when compared with FADD S194A-expressing cells (Supplementary Figure 5 ). Furthermore, Plk1 expression was higher in Jurkat cells that were stably depleted of FADD (Juo et al., 1999) than in parental Jurkat cells (Supplementary Figure 6) . We next transfected FADD S194D into FADD-deficient Jurkat cells to determine if the expressions of P-FADD and Plk1 were causally related. Plk1 expression decreased in FADD S194D-transfected FADD-deficient Jurkat cells, implying that P-FADD downregulates Plk1 expression (Supplementary Figure 6 ). Moreover, expression levels of cyclin A and cyclin B remained unchanged in FADD S194D-transfected cells when compared with FADD S194A-transfected cells. This elucidates that Plk1 decrease is mediated by P-FADD, not a secondary cell cycle effect (Supplementary Figure 7) .
We next investigated whether downregulation of Plk1 expression by P-FADD occurred via regulation of the protein degradation pathway. The decreased Plk1 expression in FADD S194D-transfected HeLa cells was significantly inhibited following treatment with the proteasome inhibitor MG132 (Figure 3b ). This indicates that P-FADD-mediated Plk1 decrease occurs through a proteasome-mediated degradation pathway.
To determine whether Plk1 was degraded by P-FADD in an ubiquitin (Ub)-dependent or -independent manner, we generated a D-box substitution mutant (S337A, L340A) of Plk1 that could not be targeted for degradation by anaphase-promoting complex/cyclosome (Lindon and Pines, 2004) . As shown in Supplementary Figure 8 , wildtype Plk1 was rapidly degraded upon exit from mitosis into G 1 phase, whereas the expression level of D-box mutant protein remained unchanged. However, the Plk1 D-box mutant was degraded with the same efficiency as that of wild-type Plk1 degradation in the presence of FADD S194D (Figure 3c ). We next determined if Plk1 degradation occurred at restrictive temperatures in ts20-BALB cells lacking E1 Ub-activating enzyme activity (Chowdary et al., 1994) . In ts20-BALB cells, FADD S194D mediated Plk1 degradation at the restrictive Tumor suppression by phosphorylated FADD M-S Jang et al temperature (39 1C) as effectively as that at the permissive temperature (35 1C), whereas the p53 level remained relatively unchanged at 39 1C (Figure 3d ). Our data indicate that the P-FADD-mediated decrease in Plk1 occurs through an Ub-independent degradation pathway. The cells released from the aphidicolin block for different times were stained with a-tubulin for detection of cytokinesis and analyzed by western blot using cell cycle detection markers such as cyclin A and cyclin B. At 16 h of release from the block, FADD S194A-transfected cells were already in G1 phase, whereas FADD S194D-transfected cells were still in cytokinesis (Figure 4a) . Moreover, cyclin A, cyclin B, and Plk1 were degraded faster in FADD S194A-transfected cells when compared with FADD S194D-transfected cells, suggesting that P-FADD caused a mitotic delay (Figure 4b ). This result is consistent with the previous study (Liu et al., 2006) . P-FADD participates in two distinct modes of cell death, depending on taxol concentration Taxol induces different types of cell death depending on the concentrations of the drug in cancer cells (Wang et al., 2000) . Lower doses (o0.2 mM) of taxol are sufficient to block mitotic progression, whereas higher concentrations (0.2-30 mM) are required for caspase activation. To determine the type of cell death to which P-FADD contributed, we overexpressed FADD mutants in HeLa cells. HeLa cells transfected with FADD S194A or FADD S194D were treated with different concentrations of taxol and cell death was analyzed by fluorescence-activated cell sorting (Figure 5a ), propidium iodide/Hoechst 33258 staining (Figure 5b ) and lactate dehydrogenase release (Supplementary Figure 9) . Low-dose (25 nM) and unstimulated FADD S194A-transfected cells did not exhibit a significant increase in cell death compared with MOCK-transfected cells ( Figure 5 ). However, cell death was moderately potentiated by FADD S194A in high-dose (30 mM) taxol-treated cells. Caspase-3 activation did not occur in low-or high-dose taxol-treated cells following FADD S194A transfection, suggesting that FADD S194A potentiates cell death via a caspase-independent mechanism in response to a high dose of taxol ( Figure 5c, Supplementary Figure 9 ). In contrast, transfection of FADD S194D potentiated cell death under all conditions tested (that is, unstimulated, low dose and high dose). However, the type of cell death mediated by FADD S194D differed in response to taxol concentration. FADD S194D induced caspase-independent cell death in unstimulated-and low-dose-treated cells, but stimulated caspase-3 activity in high-dosetreated cells (Figure 5c ). Collectively, our data indicate that P-FADD induces both caspase-dependent and caspase-independent cell death, whereas unphosphorylated FADD moderately stimulates caspase-independent cell death in high-dose taxol-treated cells. Our findings reveal that FADD phosphorylation is an important event in taxol-mediated cell death.
P-FADD possesses tumor suppressor activity in vitro and in vivo
In vitro colony formation assays and in vivo tumorigenesis assays were performed to determine if P-FADD could inhibit the oncogenic function of Plk1. We generated a HeLa cell line that overexpressed Plk1 (HeLa-Plk1) and subsequently transfected such cells with FADD S194A or S194D. Plk1 expression decreased in FADD S194D-transfected HeLa-Plk1 cells compared with FADD S194A-transfected HeLa-Plk1 cells (Figures 6a and b, middle panel) . Anchoragedependent assays revealed that HeLa-Plk1 cells transfected with FADD S194D formed fewer colonies than did cells transfected with FADD S194A (Figure 6a) . In an anchorage-independent assay on soft agar, the FADD S194D transfectants formed fewer colonies than did FADD S194A transformants (Figure 6b ). These results suggest that P-FADD suppresses cell proliferation signals. We next examined the effects of P-FADD in nude mice using a tumorigenesis assay. Nude mice were injected with HeLa-Plk1 cells overexpressing FADD S194A, S194D or with an empty vector. At 6 weeks after injection, the tumors in these mice were Tumor suppression by phosphorylated FADD M-S Jang et al dissected and weighed (Figure 6c ). The HeLa-Plk1 cells and HeLa-Plk1 cells overexpressing FADD S194A formed rapidly growing tumors, whereas the HeLaPlk1 cells overexpressing FADD S194D formed much smaller tumors (Figures 6c and d) . These data are consistent with the results of anchorage-dependent and -independent assays (Figures 6a and b) . However, the tumor-suppressor activity of FADD S194D was more potent in the nude mouse assay than in the cellular assays. Collectively, our data demonstrate the suppressor activity of P-FADD against Plk1-mediated tumorigenesis, both in vitro and in vivo.
Discussion
This study introduces FADD as a novel substrate of Plk1. P-FADD degrades Plk1 in an Ub-independent manner, establishing a negative feedback loop. Overexpression of P-FADD arrests the cell cycle, results in a cellular phenotype characterized by Plk1 depletion and suppresses the tumorigenic potential of Plk1, resulting in the in vivo phenotype of Plk1 deficiency. In addition, our findings reveal that P-FADD mediates both caspasedependent and -independent types of cell death depending on the concentration of taxol employed. Our data emphasize the pivotal importance of FADD phosphorylation in taxol-mediated cell death and provide a molecular explanation for the transition from cell cycle dysregulation to cell death. Previous studies have identified negative regulators of Plk1, including the anaphase-promoting complex/cyclosome protein, which degrades Plk1 (Eckerdt and Strebhardt, 2006) in an Ub-dependent manner, for mitotic exit. In this study we identified FADD as a negative regulator of Plk1. However, FADD degrades Plk1 in an Ub-independent manner. The Ub-independent degradation pathway induced by P-FADD seems to operate only when Plk1 is expressed beyond physiological levels, establishing an autoregulatory loop. Tumor cells are often exposed to ischemic environments where adenosine triphosphate (ATP) levels are low. Considering that Ub-independent degradation does not require ATP (Jariel-Encontre et al., 2008) , Ub-independent degradation may serve as an alternative degradation mechanism in tumor tissues when Ub-dependent degradation is not favored. Therefore, the Ub-independent degradation of an oncogene (Plk1) by a death protein (FADD) will trigger cell cycle arrest and subsequently lead to cell death when chemotherapeutics are administered. Feedback regulatory mechanisms are necessary for cellular homeostatic control. Presence of feedback regulatory mechanism between oncogene and tumor suppressor has been known. One of the best-studied networks in this category is the p53-Mdm2 negative feedback loop (Lahav, 2008) , which keeps p53 levels low under physiological conditions and switches off p53 expression at the end of a stress response. Another example is the E2F1-p27 feedback loop, where the E2F1 protein binds to the p27 promoter and induces p27 gene expression. Expression of p27 results in protein interaction with pRb to suppress E2F1 activity, thereby establishing a negative feedback mechanism (Wang et al., 2005) . Recently, we described a negative feedback mechanism between Aur-A (Aurora-A) and FAF1 (FAS-associated factor 1) (Jang et al., 2008) . Here, we describe an additional negative feedback mechanism between an oncogene and a tumor suppressor (that is, Plk1 and FADD).
Phosphorylation often serves as an important regulatory mechanism for death proteins. Phosphorylation of BAX enhances BAX proapoptotic potential (Gardai et al., 2004) , whereas phosphorylations of BAD and caspase-9 reduce proapoptotic potential (Zhou et al., 2000; Brady et al., 2005) , and phosphorylation of Bcl-2 (B-cell lymphoma 2) suppresses antiapoptotic function (Bassik et al., 2004) . Phosphorylation dissociates TRADD (tumor necrosis factor receptor 1-associated death domain protein) from the TNFR1 (tumor necrosis factor receptor 1) signaling complex I and leads to the translocation of TRADD to complex II, thereby accelerating the signal transduction process (Jiang et al., 1999) . In addition, phosphorylation appears to grant FAF1 the ability to induce mitotic arrest and cell death (Jang et al., 2008) . Here, we add FADD to the list of death proteins, the function of which is regulated via phosphorylation.
A previous report found that FADD is phosphorylated by an uncharacterized 70 kDa G 2 /M-specific kinase (Scaffidi et al., 2000) . Although CK1a (37 kDa) is also activated in G 2 /M phase and is known to phosphorylate FADD, the molecular weight of the kinase is too low to be identified as CK1a. Therefore, we propose that the above-mentioned kinase is Plk1 because of the similarity in molecular weight (70 kDa) and the activation of Plk1 during G 2 /M phase. It remains possible that FADD is phosphorylated by other kinase(s) upon taxol treatment, in addition to Plk1. Considering that phosphorylation of FADD is almost completely inhibited by depletion of Plk1, two possibilities arise. One is that Plk1 is the only kinase that acts on FADD in response to taxol. Another is that Plk1 might interact with other kinase(s) that phosphorylate FADD, such as CK1a. Therefore, the depletion of Plk1 influences the action of other kinase(s). Our unpublished data suggest that Plk1 interacts with CK1a, providing support for the latter possibility. Further studies are needed to resolve this question.
Our data show that P-FADD mediates caspasedependent and -independent cell death pathways. Therefore, P-FADD does not seem to influence the type of cell death. Other factors, such as cellular energy levels, concentration of chemotherapeutics or proteins such as FADD-like interleukin-1beta-converting enzyme-inhibitory protein (FLIP) (that is, an endogenous inhibitor of caspase-8), might influence the chosen death pathway (Zong et al., 2004; Lu¨schen et al., 2005) . However, it should be noted that the phosphorylation site, Ser-194, is located outside of the death domain and death effector domain, the two well-known proteininteracting domains. Therefore, it is possible that phosphorylation of FADD might induce conformational changes that facilitate the interaction of FADD with downstream signaling proteins such as caspase-8 and RIP1.
Tumor-suppressing potential has been reported in other death proteins such as SMAC, BAX and caspase-8 (Arnt et al., 2002; Yamaguchi and Wang, 2006; Krelin et al., 2008) . However, this property has not been studied in conjunction with their phosphorylation status. In addition, interactions of death proteins with cell cycle kinases have not been studied. It would be interesting to know if the negative feedback regulation of cell cycle kinases by death proteins in response to chemotherapeutics was a common phenomenon.
The FADD protein exhibited tumor suppressor activity in vivo and in vitro. However, tumor-suppressor activity was more potent in vivo than in vitro. Overexpression of FADD blocks endothelial sprouting, implying that FADD has a physiological role in modulating angiogenesis (Zhande et al., 2007) . Considering that the in vivo activity of FADD includes the death-promoting potential shown in this study and the antiangiogenic potential, the activity difference in vivo and in vitro might be explained by the antiangiogenic potential of FADD. Further study is needed to determine if phosphorylation is also key to the antiangiogenic activity of FADD.
Materials and methods
Antibodies, treatments and cell lines
Mouse anti-Plk1 antibody was obtained from Invitrogen (Carlsbad, CA, USA). Anti-FLAG, anti-a-tubulin and antimouse tetramethyl rhodamine isothiocyanate (TRITC)-conjugated IgG antibodies were obtained from Sigma (St Louis, MO, USA). Anti-FADD and anti-p53 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-P-FADD was purchased from Cell Signaling (Beverly, MA, USA). Aphidicolin, taxol and MG132 were purchased from Sigma. HeLa cells were cultured at 37 1C under 5% CO 2 in Dulbecco's modied Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and 0.1% penicillin/streptomycin solution. The ts20-BALB cells were kindly provided by Dr Harvey Ozer (International Center for Public Health, NJ, USA).
Plasmids construction, mutagenesis and RNA interference Plk1 and its deletion constructs were cloned into the pGEX 4T-1 vector. The Plk1 substitution mutant (K82M) and FADD substitution mutants (S194A, S194D) were generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Scrambled small interfering RNA and Plk1 small interfering RNA targeting the sequence 5 0 -CCATTGGGTGTATCATGTA-3 0 were provided by Qiagen (Valencia, CA, USA).
Immunoprecipitation
Cells were lysed in mammalian lysis buffer (Park et al., 2005) . Cell debris was removed by centrifugation and the lysates were incubated for 6 h at 4 1C in the presence of anti-FADD antibody and protein A/G-sepharose beads (Santa Cruz Biotechnology). Immunoprecipitates and whole cell lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subjected to immunoblotting.
Gel filtration chromatography
After treatment with taxol (0 or 25 nM), HeLa cells were lysed in a buffer containing 20 mM Tris-Cl, pH 7.4, 1 mM phenylmethylsulfonyl fluoride and 0.1% 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate). Samples were subjected to gel filtration chromatography at a flow rate of 0.5 ml/min on a Superose 6 column with the AKTA fast protein liquid chromatography system (GE Healthcare). The fast protein liquid chromatography analysis and size markers were described previously (Jang et al., 2008) .
GST pull-down assay GST-full length and GST-truncated mutant Plk1 proteins were purified from bacteria using glutathione-sepharose beads (GE Healthcare). Purified GST-fusion proteins coupled to glutathione-sepharose 4B were incubated for 4 h in binding buffer (50 mM HEPES, pH 7.6, 50 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-40 and 10% glycerol) at 4 1C with 35 S-methionine-labeled Plk1, which had been translated in vitro using the TNT-coupled transcription/translation system (Promega, Madison, WI, USA). The precipitated proteins were extensively washed with binding buffer, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and detected by autoradiography.
In vitro kinase assay Immunoprecipitates prepared from cell lysates or recombinant Plk1 (MBL, Hamamatsu, Japan) was incubated for 30 min at 30 1C with GST or GST fusion protein of FADD in the presence of [g-32 P]ATP (Jang et al., 2008) . After reaction, the bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis, and phosphorylated proteins were detected by autoradiography.
Immunofluorescence staining HeLa cells transfected with the indicated plasmids and pEGFP growing on coverslips were synchronized at G1 using aphidicolin (1 mg/ml) for 13 h. Cells released for different times from the aphidicolin block were fixed with 3.7% paraformaldehyde. After two washes in 0.1% Triton X-100/phosphatebuffered saline, cells were incubated with an anti-a-tubulin antibody. Finally, DNA was stained with DAPI (4,6, -diamidino-2-phenylinodole) and cells were counted under a fluorescence microscope. After stimulation, cells were stained with Hoechst 33258 (Sigma) and propidium iodide during the last 20 min. The stained nuclei were then visualized using a fluorescence microscope. Four fields in the plates were counted and data were expressed as percentage of propidium iodidepositive nuclei/total nuclei. The nuclear stain, Hoechst 33258, is membrane permeable and was therefore used to determine the total number of cells in each field.
Flow cytometry
Membrane phosphatidylserine translocation was assessed via annexin-V staining. Cells were transfected with MOCK or FLAG-FADD mutants. At 36 h after transfection, cells were pretreated with z-VAD (Calbiochem, La Jolla, CA, USA) for 2 h. After 2 h of pretreatment with z-VAD, cells were subsequently treated with taxol and z-VAD for 12 h. After stimulation, cells were gently washed with phosphate-buffered saline and resuspended in 200 ml of binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl and 2.5 mM CaCl 2 ). Annexin-V-fluorescein isothiocyanate (BD Biosciences, San Jose, CA, USA) and propidium iodide (Sigma) were then added to the cells and the mixture was incubated at room temperature for 15 min in the dark. Binding buffer was added to the tube and analyzed by flow cytometry (FACS Caliber, BD Biosciences).
Caspase-3 activity
At 48 h after transfection, cells were harvested in ice-cold lysis buffer (Peptron, Daejeon, Korea). The lysates were clarified by centrifugation and the supernatants were used in caspase-3 assays. Reaction buffer containing 10 mM dithiothreitol and 2.5 mM DEVD-AMC as substrates (Peptron) were added to each sample and incubated at 37 1C for 30 min. Caspase-3 activity was detected by measuring the relative fluorescence intensity at 460 nm following excitation at 360 nm using Luminescence Spectrometer LS50B (Perkin-Elmer, Wellesley, MA, USA).
Colony formation assay
HeLa cells, Plk1-overexpressing HeLa (HeLa-Plk1) cells or HeLa-Plk1-overexpressing FADD S194A or FADD S194D cells were used. The colony formation assay was performed in a monolayer culture by plating cells in six-well plates at a density of 100 cells per well. After 2 weeks of incubation, cells were stained with crystal violet. To study colony formation in soft agar, cells were plated at a density of 1 Â 10 3 cells per well in 0.3% top agar. After 3 weeks, the surviving cells were fixed and stained with crystal violet. Colonies were photographed and counted.
In vivo tumorigenesis
We maintained 5-week-old male mice (Japan SLC, Hamamatsu, Japan). All mice were maintained in the animal facility of Chungnam National University, College of Veterinary Medicine. Animal studies were conducted in accordance with the institutional guidelines for the care and use of laboratory animals. HeLa cells, HeLa-Plk1 cells or HeLa-Plk1-overexpressing FADD S194A or FADD S194D cells were used in the tumorigenesis assays. We subcutaneously injected 5 Â 10 6 cells in 0.1 ml of phosphate-buffered saline into the flanks of 5-week-old male mice (six mice per cell line). Tumors were measured every 7 days with calipers and tumor volume was calculated according to the following formula: volume ¼ 0.52 Â width Â length Â height. 
